Figure 2From: The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study Odds ratios for developing colorectal cancer in different MPRs for selective COX-2 inhibitors. (Note: Significant odds ratios are at 10% and 20% of 5-year cumulative usage, at 10% to 40% of 3-year usage, at 10% to 80% of 1-year usage, and at 30% to 60% and 80% of 6-month usage).Back to article page